MIR4516: A Potential Drug Target and Biomarker (G100616258)

MIR4516: A Potential Drug Target and Biomarker

Molecular Imaging Research and Cancer Therapy (MIR4516) is a drug development program focused on targeting cancer cells with imgemustin, a small molecule drug that inhibits the production of energy in cancer cells. In preclinical studies, imgemustin has been shown to be an effective treatment for various types of cancer, including lung, breast, and ovarian cancer.

The MIR4516 drug target is a specific protein called heat shock protein (HSP) 70 (HSP70), which is a protein that is expressed in high levels in cancer cells and plays a critical role in their survival and growth. By targeting HSP70, MIR4516 aims to inhibit the ability of cancer cells to produce energy, leading to a decrease in cell proliferation and a potential therapeutic effect.

HSP70 is a transmembrane protein that plays a central role in various cellular processes, including DNA replication, protein folding, and stress response. It is well-known that HSP70 can be modified by various post-translational modifications, such as phosphorylation, acetylation, and ubiquitination, which can alter its stability and function.

MIR4516 focuses on modifying HSP70 through targeted mutations to create a specific variant of HSP70 that is less stable than wild-type HSP70. This modified form of HSP70 is then introduced into cancer cells to test its effectiveness as a drug.

In preclinical studies, MIR4516 has shown to be a powerful inhibitor of HSP70-mediated processes that are critical for cancer cell growth and proliferation. For example, studies have shown that MIR4516 can inhibit the formation of new blood vessels in cancer cells, which is a critical source of oxygen and energy for their growth.

Additionally, MIR4516 has been shown to reduce the amount of mitochondria in cancer cells, which are the primary sources of energy for these cells. This reduction in mitochondrial density can lead to a decrease in the production of energy by cancer cells, leading to a potential therapeutic effect.

MIR4516 has also been shown to be effective in treating various types of cancer, including lung, breast, and ovarian cancer. In preclinical studies, MIR4516 has been shown to be effective in treating these cancers by inhibiting the production of new blood vessels in the tumors, which is a critical source of oxygen and energy for cancer cell growth.

In addition to its potential therapeutic effects, MIR4516 also has the potential to serve as a biomarker for cancer. By measuring the levels of HSP70 in cancer cells before and after treatment, researchers can monitor the effectiveness of MIR4516 and determine if it is effectively targeting the HSP70-mediated processes that are critical for cancer cell growth.

Overall, MIR4516 is a promising drug target and biomarker for cancer treatment. Its ability to inhibit the production of energy in cancer cells and its potential to treat various types of cancer make it an attractive candidate for further development.

Protein Name: MicroRNA 4516

The "MIR4516 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4516 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR4519 | MIR451A | MIR451B | MIR452 | MIR4520-1 | MIR4520-2 | MIR4521 | MIR4524A | MIR4524B | MIR4525 | MIR4526 | MIR4527 | MIR4527HG | MIR4529 | MIR4530 | MIR4531 | MIR4533 | MIR4534 | MIR4535 | MIR4536-1 | MIR4536-2 | MIR4537 | MIR4538 | MIR4539 | MIR454 | MIR4540 | MIR455 | MIR4632 | MIR4633 | MIR4634 | MIR4635 | MIR4638 | MIR4639 | MIR4640 | MIR4641 | MIR4642 | MIR4644 | MIR4645 | MIR4646 | MIR4647 | MIR4648 | MIR4649 | MIR4650-1 | MIR4650-2 | MIR4651 | MIR4652 | MIR4653 | MIR4655 | MIR4656 | MIR4657 | MIR4658 | MIR4659A | MIR4659B | MIR466 | MIR4660 | MIR4661 | MIR4662A | MIR4663 | MIR4664 | MIR4665 | MIR4666A | MIR4666B | MIR4667 | MIR4668 | MIR4669 | MIR4670 | MIR4671 | MIR4672 | MIR4673 | MIR4674 | MIR4675 | MIR4676 | MIR4677 | MIR4679-1 | MIR4679-2 | MIR4680 | MIR4681 | MIR4684 | MIR4685 | MIR4686 | MIR4687 | MIR4688 | MIR4689 | MIR4690 | MIR4691 | MIR4692 | MIR4693 | MIR4694 | MIR4695 | MIR4697 | MIR4697 host gene (non-protein coding) | MIR4698 | MIR4699 | MIR4700 | MIR4701 | MIR4703 | MIR4704 | MIR4706 | MIR4707 | MIR4708